普罗布考对脑梗塞患者血液流变学及凝血相关指标的影响

doi:10.3969/j.issn.1006-6233.2020.04.020

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1242 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的:研究普罗布考对脑梗塞患者血液流变学及凝血相关指标的影响。方法:纳入2017年12月至2018年12月于我院收治的86例脑梗塞患者为对象,按抽签随机方法分为两组,各43例,其中对照组予以常规基础治疗,观察组在基础治疗前提下加用普罗布考,均持续治疗4周。对比两组临床疗效及治疗前后血浆黏度、全血高切黏度、全血低切黏度、活化部分凝血活酶时间、凝血酶时间、纤维蛋白原变化,分析治疗前后超敏C-反应蛋白、金属基质蛋白酶-9变化情况,并观察两组治疗期间不良反应发生情况。结果:观察组总有效率为90.70%,对照组总有效率为74.42%,差异有统计学意义(P<0.05)。观察组治疗后血浆黏度、全血高切黏度、全血低切黏度均显著低于治疗前及对照组治疗后(P<0.05),且上述指标治疗前后差值均显著低于对照组(P<0.05)。观察组治疗后活化部分凝血活酶时间、凝血酶时间显著高于治疗前及对照组治疗后(P<0.05),且上述指标治疗前后差值均显著高于对照组(P<0.05);观察组治疗后纤维蛋白原显著低于治疗前及对照组治疗后(P<0.05),且治疗前后差值显著低于对照组(P<0.05)。观察组治疗后血清超敏C-反应蛋白、金属基质蛋白酶-9显著低于治疗前及对照组治疗后(P<0.05),且上述指标治疗前后差值均显著低于对照组(P<0.05)。观察组不良反应发生率为11.63%,对照组不良反应发生率为18.60%,差异无统计学意义(P>0.05)。结论:普罗布考治疗脑梗塞疗效确切,能有效降低血浆黏度、全血高切黏度、全血低切黏度,改善血液流变学及凝血功能,减轻脑梗塞后炎症反应,安全性较好。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	张晓杰
	郭爱红
	李雁君

关键词 ：脑梗塞, 普罗布考, 血液流变学, 凝血功能, 炎症反应

Abstract：Objective: To study the effect of probucol on Hemorheology and coagulation in patients with cerebral infarction. Methods: 86 patients with cerebral infarction admitted to our hospital from December 2017 to December 2018 were included in the study. They were randomly divided into two groups, 43 in each group. The control group was given routine basic treatment, while the observation group was given probucol on the premise of basic treatment, which lasted for 4 weeks. The changes of plasma viscosity, whole blood high shear viscosity, whole blood low shear viscosity, activated partial thromboplastin time, thrombin time and fibrinogen were compared before and after treatment. The changes of hypersensitive C-reactive protein and matrix metalloproteinase-9 before and after treatment were analyzed, and the adverse reactions during treatment were observed. Results: The total effective rate was 90.70% in the observation group and 74.42% in the control group (P<0.05). The plasma viscosity, whole blood high shear viscosity and whole blood low shear viscosity in the observation group were significantly lower than those before treatment and after treatment in the control group (P<0.05), and the difference of the above indexes before and after treatment was significantly lower than that in the control group (P < 0.05). After treatment, the activated partial thromboplastin time and thrombin time in the observation group were significantly higher than those before treatment and after treatment in the control group (P < 0.05), and the difference of the above indexes before and after treatment was significantly higher than that in the control group (P<0.05); after treatment, the fibrinogen in the observation group was significantly lower than that before and after treatment in the control group (P < 0.05), and the difference before and after treatment was significantly lower than that in the control group (P<0.05). After treatment, the levels of serum high-sensitivity C-reactive protein and matrix metalloproteinase-9 in the observation group were significantly lower than those before and after treatment in the control group (P<0.05), and the differences of the above indexes before and after treatment were significantly lower than those in the control group (P < 0.05). The incidence of adverse reactions was 11.63% in the observation group and 18.60% in the control group (P>0.05). Conclusion: Probucol is effective in the treatment of cerebral infarction. It can effectively reduce plasma viscosity, whole blood high shear viscosity, whole blood low shear viscosity, improve hemorheology and coagulation function, reduce inflammation after cerebral infarction, and has good safety.

Key words： Cerebral infarction Probucol Hemorheology Coagulation function Inflammatory response

基金资助:陕西省科学技术厅研究项目,(编号:2017SF-282)

通讯作者: 李雁君

引用本文:

张晓杰, 郭爱红, 李雁君. 普罗布考对脑梗塞患者血液流变学及凝血相关指标的影响[J]. 河北医学, 2020, 26(4): 609-615.
ZHANG Xiaojie, GUO Aihong, LI Yanjun. Effects of Probucol on Hemorheology and Coagulation Related Indexes in Patients with Cerebral Infarction. HeBei Med, 2020, 26(4): 609-615.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2020.04.020 或 http://www.hbyxzzs.cn/CN/Y2020/V26/I4/609

[1] 黄晶晶.急性脑梗死后自发出血性转化的相关危险因素分析[J].广西医科大学学报,2017,34(9):1307~1309.
[2] Zerna C, Hegedus J, Hill MD. Evolving Treatments for acute ischemic stroke[J]. Circ Res, 2016, 118(9):1425~1442.
[3] Jia C, Wei C, Hu M, et al. Correlation between antiplatelet therapy in secondary prevention of acute cerebral infarction and cerebral microbleeds: a susceptibility-weighted imaging (SWI) study[J].Xray Sci Technol, 2018, 26(4):623~633.
[4] Nitta N, Nozaki K. Treatment for large cerebral infarction: past, pesent, and future[J]. World Neurosurg, 2015, 83(4):483~485.
[5] Li Y, Li M, Zhang X, et al. Clinical features and the degree of cerebrovascular stenosis in different types and subtypes of cerebral watershed infarction[J]. BMC Neurol, 2017, 17(1):166~173.
[6] Fu H, Li G, Liu C, et al. Probucol prevents atrial ion channel remodeling in an alloxan-induced diabetes rabbit model[J]. Oncotarget, 2016, 7(51):83850~83858.
[7] 马丽苹,高义,王晓鹏.瑞舒伐他汀联合普罗布考对老年脑梗死患者颈动脉粥样硬化、血脂及炎性因子的研究[J].中国循证心血管医学杂志,2016,8(3):335~338.
[8] 张建强,高红安,宋程光,等.普罗布考联合阿司匹林溶解治疗颈动脉斑块脑梗死的临床效果观察[J].现代生物医学进展,2017,17(5):129~132.
[9] 任琳,王国俊.普罗布考对脑梗塞进展期患者APTT、纤维蛋白原及血液流变学的影响[J].中国现代医学杂志,2017,27(6):119~122.
[10] Manli Z, Lunzhong Z, Zeying W, et al. Dynamic analysis of blood pressure changes in progressive cerebral infarction[J]. Int Health, 2015, 7(4):293~297.
[11] 张冰,马金国,吴刚,等.普罗布考对心衰大鼠心肌MMP-3、TIMP-3及OPN表达的影响[J].哈尔滨医科大学学报,2015,49(2):115~120.
[12] Gwon JG, Kwon TW, Cho YP, et al. Analysis of risk factors for cerebral microinfarcts after carotid endarterectomy and the relevance of delayed cerebral infarction[J].Clin Neurol, 2017, 13(1):32~37.